Loading
Loading
Healthcare
Executive compensation benchmarks for 55 public companies in the pharmaceutical preparations industry.
$11.6M
55
$163.3M
80:1
Median
$11,636,917
Average
$15,655,169
25th Percentile
$8,112,216
75th Percentile
$18,189,681
Minimum
$107,530
Maximum
$163,293,744
Avg Pay Ratio
80:1
Companies
55
Click any company to see full compensation breakdown
The median pharmaceutical preparations CEO compensation is $11,636,917, based on 55 public companies. The average is $15,655,169. Note that CEO compensation includes salary, bonus, stock awards, option awards, and other compensation.
Matthew Gline of Roivant Sciences Ltd. is the highest paid pharmaceutical preparations CEO, with total compensation of $163,293,744 in FY2025.
The average CEO-to-median-employee pay ratio in the pharmaceutical preparations industry is 80:1. This means the average CEO earns 80 times what the median employee earns.
Data sourced from SEC filings (DEF 14A proxy statements). Last updated: May 31, 2026. Compensation figures are total annual compensation including salary, bonus, stock awards, and other compensation.
Compare CEO compensation across different industries or research specific companies.
| Company | CEO | Total Comp |
|---|---|---|
| Roivant Sciences Ltd. ROIV | Matthew Gline | $163.3M |
| JOHNSON & JOHNSON JNJ | J. Duato | $32.8M |
| ELI LILLY & Co LLY | David A. Ricks | $30.2M |
| Cogent Biosciences, Inc. COGT | Andrew Robbins | $27.8M |
| AbbVie Inc. ABBV | Robert A. Michael | $27.3M |
| ABBOTT LABORATORIES ABT | Robert B. Ford, | $24.2M |
| ASTRAZENECA PLC AZN | Pascal Soriot | $23.8M |
| PTC THERAPEUTICS, INC. PTCT | Matthew B. Klein | $23.3M |
| BIOMARIN PHARMACEUTICAL INC BMRN | Alexander Hardy | $21.9M |
| VERTEX PHARMACEUTICALS INC / MA VRTX | Reshma Kewalramani | $21.1M |
| Merck & Co., Inc. MRK | Robert M. Davis | $20.8M |
| MADRIGAL PHARMACEUTICALS, INC. MDGL | Bill Sibold | $19.2M |
| TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA | Richard Francis | $19.2M |
| Jazz Pharmaceuticals plc JAZZ | Philip L. Johnson | $18.8M |
| RHYTHM PHARMACEUTICALS, INC. RYTM | David P. Meeker | $17.5M |
| Organon & Co. OGN | Kevin Ali | $15.8M |
| SUPERNUS PHARMACEUTICALS, INC. SUPN | Jack A. Khattar | $15.5M |
| CORCEPT THERAPEUTICS INC CORT | Joseph K. Belanoff | $15.3M |
| Viatris Inc VTRS | Scott A. Smith | $15.3M |
| BridgeBio Pharma, Inc. BBIO | Neil Kumar | $14.9M |
| Alnylam Pharmaceuticals, Inc. ALNY | Yvonne L. Greenstreet | $14.9M |
| INSMED Inc INSM | William H. Lewis | $14.5M |
| Avidity Biosciences, Inc. RNA | Sarah Boyce | $14.2M |
| Apellis Pharmaceuticals, Inc. APLS | Cedric Francois | $13.3M |
| Protagonist Therapeutics, Inc PTGX | Dinesh V. Patel | $12.9M |
| Acadia Pharmaceuticals Inc. ACAD | Stephen R. | $12.2M |
| CYTOKINETICS INC CYTK | Robert I. Blum | $11.9M |
| Pacira BioSciences, Inc. PCRX | Frank Lee | $11.6M |
| LIGAND PHARMACEUTICALS INC LGND | Todd C. Davis | $11.5M |
| Nuvalent, Inc. NUVL | James R. Porter | $11.4M |
| UNITED THERAPEUTICS Corp UTHR | Michael Benkowitz | $11.3M |
| Axsome Therapeutics, Inc. AXSM | Herriot Tabuteau | $10.3M |
| ANI PHARMACEUTICALS INC ANIP | Nikhil Lalwani | $10.3M |
| Merus N.V. MRUS | Sven (Bill) Ante Lundberg | $9.7M |
| Arcus Biosciences, Inc. RCUS | Terry Rosen | $9.7M |
| BeOne Medicines Ltd. ONC | John V. Oyler | $9.3M |
| IONIS PHARMACEUTICALS INC IONS | Brett P. Monia | $9.2M |
| PERRIGO Co plc PRGO | Patrick Lockwood-Taylor | $9.0M |
| ARROWHEAD PHARMACEUTICALS, INC. ARWR | Christopher Anzalone | $9.0M |
| Amneal Pharmaceuticals, Inc. AMRX | Chirag Patel | $8.7M |
| Amphastar Pharmaceuticals, Inc. AMPH | Jack Yongfeng Zhang | $8.3M |
| Alkermes plc. ALKS | Richard F. Pops | $7.9M |
| Harmony Biosciences Holdings, Inc. HRMY | Jeffrey M. Dayno | $7.9M |
| Sarepta Therapeutics, Inc. SRPT | Douglas S. Ingram | $7.8M |
| REGENERON PHARMACEUTICALS, INC. REGN | Leonard S. Schleifer | $7.3M |
| Xencor Inc XNCR | Bassil I. Dahiyat | $5.5M |
| Innoviva, Inc. INVA | Pavel Raifeld | $5.4M |
| PHIBRO ANIMAL HEALTH CORP PAHC | Jack C. Bendheim | $5.3M |
| Schrodinger, Inc. SDGR | Ramy Farid | $4.1M |
| Grifols, S.A. GRFS | Jose Ignacio Abia Buenache | $3.5M |
| COLLEGIUM PHARMACEUTICAL, INC COLL | Vikram Karnani | $1.7M |
| Royalty Pharma plc RPRX | Christopher Hite | $1.3M |
| Summit Therapeutics Inc. SMMT | Mahkam Zanganeh | $1.0M |
| KAMADA LTD KMDA | Amir London | $916K |
| Abivax S.A. ABVX | Claret Financing | $108K |